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Secular trends in smoking in relation to prevalent and 
incident smoking-related disease: A prospective population-
based study
Philip Tonnesen1, Jacob L. Marott2, Børge Nordestgaard2, Stig Egil Bojesen2, Peter Lange1
ABSTRACT
INTRODUCTION We examined changes in smoking habits in the general population 
according to prevalence and incidence of chronic diseases affected by smoking.
METHODS We included 12283 individuals enrolled from 2003 in the Copenhagen 
General Population Study and re-examined from 2014.  Participants were classified 
as either healthy or suffering from chronic obstructive pulmonary disease (COPD), 
asthma, diabetes mellitus, heart disease or stroke. 
RESULTS At entry, smoking prevalence was 15.4% in healthy participants, 29.8%  with 
COPD, 15.8% with asthma, 21.7 % with diabetes mellitus, 17.2 % with ischemic 
heart disease/heart failure and 18.6% in participants with previous stroke. 
Smoking prevalence declined during the 10 years of observation. Among healthy 
subjects who developed one of the above mentioned diseases during follow-up, 
those who developed COPD had the highest initial smoking prevalence (51.5%). 
Quit rates were highest in those who developed asthma resulting in smoking 
prevalence of 8.2% versus 27.7% in COPD. After adjustment for age, smoking 
severity and genotype previously associated with heavy smoking (CHRNA3 
rs1051730 AA), significant predictors of quitting were new diagnosis of ischemic 
heart disease/heart failure (OR=2.33, 95 % CI: 1.61–3.42), new diagnosis of 
asthma (OR=1.84, 95% CI: 1.18–2.90) and low number of pack-years. 
CONCLUSIONS Individuals with prevalent smoking related diseases continued to 
smoke more than healthy individuals. Incident heart disease and asthma, but 
not incident COPD, stroke or diabetes were associated with a higher chance 
of quitting. Special focus on smokers with COPD, asthma, diabetes, stroke and 
ischemic heart disease/heart failure is warranted to decrease smoking prevalence 
in these groups. Smokers with a new diagnosis of diabetes, stroke and COPD need 
special smoking cessation support. 
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INTRODUCTION
Tobacco smokers lose approximately 10 years of 
expected life duration compared to never smokers1. 
Long-term smoking is one of the most important 
preventable risk factors for morbidity and mortality, 
especially regarding chronic obstructive pulmonary 
disease (COPD), lung cancer and atherosclerotic 
cardiovascular disorders.  Smokers with asthma have 
more symptoms and need a higher dose of inhaled 
steroids and more often experience faster disease 
progression2. COPD patients who quit smoking have 
a lower decline in lung function, lower morbidity 
and lower mortality compared with COPD patients 
who continue to smoke3. Also in diabetes, continuous 
smoking is a predictor of increased mortality4,5. 
Although smoking cessation is one of the most 
cost-effective interventions in medicine, it is still 
underused6,7. 
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Smoking prevalence in patients with asthma but not 
with COPD has almost halved in Sweden from 2005 
to 20128. In another study of 4636 smokers from 7 
centers in North Europe followed for 10 years, 39 % 
stopped smoking. In this cohort asthma, wheeze, hay 
fever, chronic bronchitis, diabetes and hypertension did 
not significantly predict smoking cessation, but smokers 
hospitalized for ischemic heart disease (IHD) during 
the study period were more prone to stop smoking9. 
As both presence and in particular incidence 
of smoking related disease may open a window of 
opportunity for motivation to quit, we found it of interest 
to examine secular trends in smoking prevalence over 
a period of 10 years in the general population. We 
compared smoking habits in smokers without chronic 
disease with individuals with either prevalent or incident 
COPD, asthma, diabetes mellitus (DM), stroke and heart 
disease, and explored the presence of these conditions 
as potential predictors of quitting.
 
METHODS
Study population
We identified 12283 individuals who participated 
in the second examination of the Copenhagen 
General Population Study from 6 February 2014 
to 9 March 2017, who had also participated in the 
first examination 10 years earlier. This was a Danish 
contemporary population-based cohort study, which 
was approved by Herlev and Gentofte Hospital and 
the regional ethics committee (H-KF-01-144/01) and 
conducted according to the Declaration of Helsinki10,11. 
All participants provided written informed consent.
In Denmark, all individuals are assigned a unique 
identification number, at birth or at immigration, and 
recorded in the national Danish Civil Registration 
System. Based on age and sex, individuals living 
in the Capital Region of Denmark were randomly 
selected and invited to participate from the national 
Danish Civil Registration System to reflect the adult 
Danish population (response rate was about 45%). All 
participants completed a comprehensive questionnaire 
and underwent a physical health examination. 
Questionnaires were reviewed at the day of attendance 
by a healthcare professional and the participant. 
In the analyses, we included the genetic variant 
CHRNA3 rs1051730, which in previous studies has 
been shown to be associated with higher tobacco 
consumption12-14. The study staff performing 
the genotyping were not aware of participants 
characteristics including their smoking status. The 
ABI PRISM 7900HT Sequence Detection System 
(Applied Biosystems Inc.) was used to genotype 
CHRNA3 rs1051730 with TaqMan assays. Genotyping 
was verified by DNA sequencing, and call-rates were 
above 99.8% as we performed re-runs twice.
In this paper we included 10251 subjects who all 
attended the first and second examination. In the 
analyses of smoking cessation, we only included 2563 
individuals who were smokers at the first examination 
round.  
Definitions of smoking habits
• Smokers: self-reported daily smokers of any form of 
tobacco.
• Ex-smokers: individuals reporting having stopped 
smoking before the first examination.
• Never smokers: self-reported never smokers.
• Quitters: current smokers at first examination and 
former smokers at second examination. 
• Continued smokers: current smokers at both surveys. 
There was no biochemical verification of non-
smoker status.
Definitions of prevalent chronic diseases
Healthy smokers
These were chosen at the first examinations as 
the reference group and defined according to the 
following: 1) Spirometry without presence of airflow 
limitation, which was defined as forced expiratory 
volume in 1 second (FEV
1
)/forced vital capacity 
(FVC) <0.7 at entry or follow-up; 2) No hospital 
admissions for COPD or asthma during the follow-
up period; 3) No self-reported COPD or asthma at 
entry or at follow-up; 4) No self-reported medicine 
for asthma/COPD at entry or follow-up; 5) No 
self-reported IHD, heart failure (HF), stroke or 
diabetes mellitus (DM) at study entry; 6) No hospital 
admission in the follow-up period for IHD/HF, DM 
or stroke; and 7) No self-reported use of insulin or 
other medicine for DM at study entry or at follow-up. 
COPD  
Defined at study entry as one or more of the following: 
1) Hospital admission for COPD before study entry; 
2) Self-reported COPD at follow-up with time of 
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diagnosing longer than the interval between the two 
examinations; 3) Self-reported medicine for asthma/
COPD at study entry; and 4) No self-reported asthma.
Asthma 
Defined at study entry as one or more of the following: 
1) Hospital admission for asthma before study entry; 
2) Self-reported asthma at study entry; 3) Self-
reported medicine for asthma/COPD at study entry; 
and 4) No criteria fulfilling the above- mentioned 
COPD definition.
 
IHD and/or HF 
Defined at study entry as either hospital admission 
for IHD or HF before study entry or self-reported 
previous ‘heart attack’ at study entry.
 
Stroke
Defined at study entry as either hospital admission for 
stroke before study entry or self-reported previous 
stroke at study entry.
DM 
Defined at study entry as either hospital admission 
for DM before study entry or self-reported diabetes 
at study entry.
Definitions of incident chronic conditions
New diagnosis of COPD
Defined as one or more of the following: 1) Hospital 
admission for COPD between entry and follow-up; 2) 
Self-reported COPD during follow-up with time of 
diagnosing shorter than the interval between the two 
examinations; 3) Self-reported medicine for asthma/
COPD during follow-up; 4) No self-reported asthma 
during follow-up; and 5) No COPD at study entry 
according to the COPD definition above.
New diagnosis of asthma 
Defined as one or more of the following: 1) Hospital 
admission for asthma between study entry and follow-
up; 2) Self-reported asthma during follow-up; 3) Self-
reported medicine for asthma/COPD during follow-
up; and 4) No asthma at study entry according to the 
above asthma definition.
New diagnosis of IHD/HF
Defined as hospital admission for IHD or HF between 
study entry and follow-up and no IHD or HF at study 
entry according to the above definition.
New diagnosis of stroke
Defined as hospital admission for stroke between 
study entry and follow-up and no stroke at study entry 
according to the above definition.
New diagnosis of DM
Defined as one or more of the following: 1) Hospital 
admission for DM between study entry and end of 
follow-up; 2) Self-reported DM during follow-up; 
3) Self-reported use of insulin or other medicine for 
DM during follow-up; and 4) No DM at study entry 
according to the above DM definition.
 
The ICD (International Classification of Diseases) 
codes used for the different diseases were: COPD 
(ICD-8: 491-492; ICD-10: J41-J44), asthma (ICD-8: 
493; ICD-10: J45-J46), IHD/HF (ICD-8: 410-414, 
427.09-427.11; ICD-10: I20-I25, I50), DM (ICD-8: 
249-250; ICD-10: E10-E11, E13-E14), and stroke 
(ICD-8: 430-438; ICD-10: I60-I68, G45)15. 
Statistical analysis
For demographics, Pearson’s χ2-test and analysis 
of variance were performed for categorical and 
continuous variables, respectively. The quit rate 
was calculated as the proportion of smokers at 1st 
examination who reported being former smokers 
at 2nd examination. Stepwise model selection in 
multivariable logistic regression analysis for smoking 
cessation according to the Akaike Information 
Criterion (AIC) was performed. Possible explanatory 
variables were demographic variables (sex, age, 
years in school, body mass index), smoking related 
variables (early smoking debut, heavy smoking, 
pack-years), and CHRNA3 rs1051730 genotype. The 
stepwise regression analysis was initially performed 
on the entire data set and the resulting variables 
were considered possible confounding variables 
and included in each of the disease-specific analyses 
(Table 3).
RESULTS
The total study population of individuals attending 
both the 1st and the 2nd examination of the 
Copenhagen General Population Study comprised 
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12283 individuals including 7905 healthy subjects 
and 2346 subjects with any of the investigated 
diseases already present at the first examination 
(Figure 1). Between the two examinations, 2672 
experienced incidence of new disease. The upper part 
of Figure 1 shows smoking prevalence in the group of 
healthy individuals at both examinations. The middle 
part shows smoking prevalence in individuals with 
first disease event before 1st examination. The lower 
part shows smoking prevalence in subjects who were 
healthy at study entry but experienced a disease event 
between the two examinations (incident disease). 
Among the 2346 participants with disease at study 
entry, smoking prevalence was higher than in the 
healthy participants with 15.8% among those with 
asthma and highest in those with COPD (29.8%), 
with in-between prevalences for DM (21.7%), IHD/
HF (17.2%) and stroke (18.6%) (Figure 1). Smoking 
prevalence declined from the 1st to the 2nd study, 
in all subgroups. The 10-year quit rate was 53.0% 
for the healthy subjects compared with 51.9 % for 
subjects with any disease, and a quit rate of 57.6% 
in individuals with asthma and 56.6% in those with 
COPD (Figure 1). 
Figure 1. Smoking prevalence in healthy smokers and in the different disease groups at the 1st and the 2nd 
examination for prevalent disease (upper part) and incident disease (lower part) 
1st examination 2nd examination Quit rate
0.3% with ≥3 diseases (N=44) 24.4% current smokers 11.4% current smokers 60.0%
6.3% with Asthma (N=942) 15.8% current smokers 7.9% current smokers 57.6%
20.7% current smokers 7.2% current smokers6.1% with IHD/HF (N=914) 69.0%
First disease event before 1st examination
26.3% current smokers 12.6% current smokersAny diseases (N=2672) 56.1%
2.2% with Stroke (N=331) 18.6% current smokers 10.1% current smokers 49.1%
26.7% current smokers 13.7% current smokers3.7% with DM I+II (N=552) 54.3%
Healthy population (N=7905) 15.4% current smokers 8.2% current smokers 53.0%
First disease event between examinations
3.8% with IHD/HF (N=570) 17.2% current smokers 10.8% current smokers 43.5%
23.6% current smokers 12.1% current smokers4.1% with Stroke (N=623) 54.7%
Any diseases (N=2346) 19.6% current smokers 10.4% current smokers 51.9%
51.5% current smokers 27.7% current smokers3.3% with COPD (N=501) 47.5%
2.5% with DM I+II (N=370) 21.7% current smokers 12.6% current smokers 44.3%
31.0% current smokers 11.9% current smokers0.3% with ≥3 diseases (N=42) 61.5%
3.3% with COPD (N=501) 29.8% current smokers 14.5% current smokers 56.6%
20.2% current smokers 8.2% current smokers3.4% with Asthma (N=507) 62.2%
1.8% with 2 diseases (N=274) 19.2% current smokers 11.6% current smokers 47.9%
34.8% current smokers 15.5% current smokers2.3% with 2 diseases (N=340) 57.1%
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Among the 2672 subjects who were healthy at 
study entry but experienced disease events between 
examinations, individuals with COPD had the highest 
initial smoking prevalence (51.5%) (Figure 1). In 
general, developing new disease was associated with 
a tendency towards higher quit rates especially among 
those who developed asthma (quit rate 62.2%). The 
lowest quit rate of 47.2% was observed in COPD.
Baseline demographics for the 2563 smokers at 
the 1st examination according to smoking status at 
follow-up 10 years later are shown in Table 1. Those 
who quit smoking had significantly lower pack-
years and a higher debut age of smoking. They had 
a lower number of GP visits and more of them were 
characterized as healthy.
Table 2 shows the characteristics of smokers at the 
first examination according to their health status. In 
general, those who either initially had or subsequently 
developed one of the chronic diseases were older, had 
a lower level of education, higher BMI (kg/m2), more 
pack-years and daily cigarettes smoked, and an earlier 
smoking start than healthy smokers. 
Table 3 shows predictors for quitting smoking 
between the two examinations derived from a 
multivariable logistic step-wise regression analysis 
with focus on prevalent and incident diseases. All 
models included age, sex, pack-years, heavy smoking 
and CHRNA3 genotype. The most significant 
predictors of quitting were lower pack-years, new 
diagnosis of asthma (OR=1.84, 95% CI: 1.18–2.90, 
p<0.01) and new diagnosis of IHD/HF (OR=2.33, 
95% CI: 1.61–3.42), p<0.001), whereas having one 
Smoking
quitters
Continued
smokers
p
General characteristics N=1300 N=1263
Men, n/total (%) 576/1300 (44) 565/1263 (45) 0.86
Age (years), mean (SD) 54 (9) 53 (9) 0.51
Education, n/total (%) 0.23
<8 142/1296 (11) 148/1256 (12)
8–10 708/1296 (55) 722/1256 (57)
>10 years 379/1296 (29) 322/1256 (26)
University 67/1296 (5) 64/1256 (5)
BMI (kg/m2), mean (SD) 25 (4) 26 (4) 0.36
High physical activity in leisure time, n/total (%) 525/1292 (41) 501/1252 (40) 0.83
GP visits >6, n/total (%) 61/1013 (6) 104/991 (10) <0.001
Smoking related variables
Smoking debut before age 14, n/total (%) 104/1287 (8) 135/1257 (11) 0.026
Daily tobacco consumption (g/day), mean (SD) 14 (9) 17 (9) <0.001
Years of smoking, mean (SD) 33 (10) 35 (10) <0.001
Pack-years, mean (SD) 22 (18) 28 (19) <0.001
CHRNA3 rs1051730 AA genotype, n/total (%) 133/1276 (10) 158/1239 (13) 0.08
Health status
Healthya 546/1300 (42) 484/1263 (38) 0.06
First disease event before 1st examination
Any diseases 215/1300 (17) 199/1263 (16) 0.63
COPD 77/1300 (6) 59/1263 (5) 0.19
Asthma 76/1300 (6) 56/1263 (4) 0.13
IHD/HF 40/1300 (3) 52/1263 (4) 0.19
Stroke 27/1300 (2) 28/1263 (2) 0.91
DM I+II 31/1300 (2) 39/1263 (3) 0.33
Table 1. Baseline demographics for the 2563 individuals who were smokers at the first examination in 2003–
2014 according to smoking status at the final examination in 2014–2017 
Smoking quitters: current smokers at first examination and former smokers at second examination. Continued smokers: current smokers at both surveys. a No COPD, asthma, 
IHD/HF, stroke or DM at any of the examinations. 
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of these diagnoses at study entry did not influence 
quitting rate (Table 3). The level of education and 
physical activity in leisure time had no significant 
impact on quitting.
Changes in clinical characteristics between study 
entry and follow-up for the 1300 quitters and the 
1263 continued smokers are shown in Table 1S in the 
Supplementary file. As expected, quitting smoking was 
associated with lower decline of FEV
1
 and weight gain. 
DISCUSSION
The main findings of the present study include the 
following. First, the smoking prevalence was higher 
among individuals with defined chronic diseases 
compared to healthy subjects. During the 10-year 
observation, smoking prevalence decreased by 
approximately 50% both in healthy subjects and 
in those with smoking related conditions. Most 
importantly, however, is our finding that incident 
diagnoses of IHD/HF and asthma were related to 
a higher chance of quitting compared with incident 
diagnosis of COPD, diabetes and stroke, despite 
weight increases in those who quit.
Prevalent chronic disease and smoking
Presence of any of the investigated diseases at study 
Health status Male sex Age School 
years
BMI
kg/m2
Smoking 
debut before 
age 14
Tobacco/day
≥15 g 
Pack-
years
CHRNA3 
rs1051730 
AA genotype
n/total (%) mean 
(SD)
mean 
(SD)
mean 
(SD)
n/total (%) n/total (%) mean 
(SD)
n/total (%)
Healthya 438/1030 (43) 50 (9) 10.3 (1.8) 25 (4) 90/1023 (9) 523/1030 (51) 19 (16) 114/1014 (11)
First disease event before 1st examination
Any diseases 189/414 (46) 57 (9) 9.6 (1.8) 27 (5) 49/410 (12) 266/414 (64) 30 (21) 38/402 (9)
COPD 58/136 (43) 58 (8) 9.3 (1.9) 26 (4) 15/136 (11) 106/136 (78) 37 (21) 14/134 (10)
Asthma 46/132 (35) 53 (10) 9.7 (1.9) 26 (5) 20/132 (15) 81/132 (61) 27 (19) 13/128 (10)
IHD/HF 64/92 (70) 59 (9) 9.3 (1.8) 27 (4) 15/90 (17) 49/92 (53) 30 (19) 11/88 (13)
Stroke 21/55 (38) 58 (10) 9.9 (1.6) 26 (4) 6/53 (11) 26/55 (47) 25 (19) 0/53 (0)
DM I+II 35/70 (50) 59 (8) 9.3 (1.7) 29 (6) 6/69 (9) 52/70 (74) 37 (24) 5/69 (7)
First disease event between examinations
Any diseases 307/640 (48) 57 (9) 9.7 (1.8) 26 (5) 62/635 (10) 423/640 (66) 30 (20) 71/626 (11)
COPD 105/244 (43) 57 (9) 9.7 (1.8) 26 (5) 29/242 (12) 166/244 (68) 31 (20) 35/239 (15)
Asthma 34/98 (35) 55 (9) 9.7 (1.9) 26 (4) 9/98 (9) 69/98 (70) 31 (21) 11/97 (11)
IHD/HF 107/168 (64) 58 (9) 9.6 (1.8) 27 (4) 16/167 (10) 107/168 (64) 30 (20) 10/163 (6)
Stroke 66/128 (52) 58 (9) 9.7 (1.8) 25 (4) 10/127 (8) 76/128 (59) 26 (21) 12/124 (10)
DM I+II 72/140 (51) 56 (8) 9.6 (1.8) 30 (5) 10/138 (7) 100/140 (71) 33 (17) 17/138 (12)
Table 2. Characteristics in individuals with prevalent and incident chronic diseases for the 2563 individuals 
who were smokers at the first examination in 2003–2014
a No COPD, asthma, IHD/HF, stroke or DM at any of the examinations.
OR ( 95% CI)
Confounding variables
Pack-years
<10 1.00 (reference)
10–30 0.57 (0.44–0.75)***
≥30 0.44 (0.31–0.62)***
Heavy smoking (≥15 g tobacco/day) 0.81 (0.64–1.02)
Age (years) 1.01 (1.00–1.02)
CHRNA3 rs1051730 AA genotype 0.82 (0.64–1.05)
Prevalent diseases
Multi-diseases 0.98 (0.56–1.71)
COPD 1.41 (0.95–2.10)
Asthma 1.30 (0.89–1.92)
IHD/HF 0.74 (0.46–1.18)
Stroke 0.86 (0.47–1.56)
DM I+II 0.80 (0.47–1.35)
Incident diseases
Multi-diseases 1.52 (1.02–2.28)*
COPD 0.98 (0.72–1.34)
Asthma 1.84 (1.18–2.90)**
IHD/HF 2.33 (1.61–3.42)***
Stroke 1.28 (0.87–1.90)
DM I+II 1.35 (0.93–1.98)
Table 3. Multivariable logistic regression analysis of 
predictors for quitting smoking between the two 
examinations for prevalent and incident diseases
OR: odds ratio.  All models are adjusted for the confounding variable: pack-years, 
heavy smoking, age, and CHRNA3 rs1051730 AA genotype. Stepwise model selection 
based on Akaike Information Criterion was performed among the variables in the 
columns of Table 2.  *p<0.05; **p<0.01; ***p<0.001. 
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entry was not associated with a higher chance of 
quitting compared to healthy smokers. Probably, many 
of the ever-smokers in the present study already quit 
smoking when they got the diagnosis and after that the 
quit rate was in the same range as in healthy smokers. 
Looking at the absolute smoking rates for individuals 
with prevalent asthma and IHD/HF in particular, they 
were at the same level as healthy subjects, whereas 
those with COPD had the highest smoking prevalence 
of 14.5%. In smoking cessation studies with COPD 
patients, the quit rates with all types of smoking 
cessation medication were lower compared to healthy 
smokers and especially the placebo quit rate is very 
low, indicating that COPD patients that smoke have 
more difficulties with stopping smoking16. It has 
also been reported that smoking cessation support 
is underused in smokers with COPD6,7.  For example, 
among US patients with COPD, the average annual 
prescription rate of any smoking cessation medication 
from 2007 to 2012 was only 3.6%6. Thus, this seems 
to be an area where help towards smoking cessation 
should be much more offered. 
In a Swedish study with a 7-year follow-up, smoking 
prevalence decreased from 11% to 6% (p<0.0001) 
in patients with asthma, but was almost unchanged 
in patients with COPD (28% to 26%, p=0.37)8. 
Compared with our results, the findings regarding 
asthma are similar, but the Swedish findings differ 
from ours regarding COPD, where we observed a quit 
rate of 56.6% with smoking prevalence decreasing 
from 29.8% to 14.5%.  We cannot find any plausible 
explanation for this difference regarding COPD 
especially as Sweden and Denmark have a very similar 
healthcare system.
Incident disease and smoking
The strongest predictor of quitting in our study was a 
new diagnosis of heart disease with OR=2.33. A new 
diagnosis of asthma was also significantly related to 
smoking cessation, whereas incident COPD, diabetes 
and stroke were not. It is not surprising that a new 
diagnosis results in smoking cessation and similar 
findings have been reported in the past. A Norwegian 
study with 1150 smokers followed from 2001–2 to 
2007–8 reported that an incident diagnosis of asthma 
or COPD and IHD resulted in a quit rate of 50.6% for 
both diagnosis with an OR=1.7 for quitting17. Less 
effect on quitting was reported in a US population 
study with 11191 subjects without chronic disease at 
study entry who were followed from 1992 to 2006. 
An incident diagnosis of cancer and stroke had the 
highest impact on quitting smoking, with a smaller 
effect of IHD and COPD. Smoking rates for IHD 
decreased by 40% (from 24.5% to 14.9%) while for 
COPD smoking rates decreased by 19% (from 43.8% 
to 35.3%). This means that almost 60% of patients 
with IHD who smoke continued to smoke and 
supports the notion that an incident disease calls for 
a more aggressive approach by offering support and 
medication for smoking cessation18. 
Patients with incident IHD in hospital based 
smoking cessation programs, as well as referral to 
cardiac rehabilitation, were strongly associated with 
increased smoking cessation rates after 6 months19. 
Applying this model for asthma, COPD, DM and 
stroke patients could be a way to increase quit rates.
Other predictors of quitting
We found that smokers with higher pack-years had a 
markedly lower quit rates, which is in accordance with 
previous findings9. Although previous studies have 
suggested that the genotype CHRNA3 rs1051730 AA 
is associated with nicotine dependence12-14 and we 
observed that it was more prevalent among continued 
smokers than among quitters, this genotype was not 
significantly related to quitting, suggesting that  its 
role is of minor importance compared with the role 
played by newly developed heart disease or asthma.
Limitations
The present study has some limitations. As it 
is a prospective observational study with two 
examination sessions separated by 10 years, we do 
not have information on the exact time of quitting 
or why and how the participants quit smoking, i.e. 
if they used support and/or medication or were still 
using smokeless tobacco. In addition, we do not 
have information on their nicotine dependence or 
biochemical verification of quitting. However, as 
this was not a study with a focus on smoking but on 
several other health parameters, the participants had 
no strong reasons not to declare their real smoking 
status. An indirect verification that the quitters had 
reported their real smoking status is the observation 
of substantial weight gain in those who reported 
quitting compared with the continued smokers. 
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CONCLUSIONS
Smoking rates declined substantially from 2003 to 
2014 in our study population. However, individuals 
with prevalent smoking related diseases continued to 
smoke more than healthy individuals. Incident heart 
disease and asthma, but not COPD, stroke or diabetes, 
were related to a higher chance of quitting. Offering 
adequate smoking cessation treatment and focus on 
the window of opportunity in those with incident 
disease should be considered. 
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